Prague (ots) – The SHARP-study has shown that lowering LDL cholesterol with ezetimibe/simvastatin leads to a significant reduction in major atherosclerotic events among CKD-patients. Whether it also has a favourable effect on renal disease progression was another of the issues addressed by the SHARP study [abstract no. 2509]. In the ezetimibe/simvastatin group, fewer patients reached [...]
Tag Archive > Myocardial Infarction
Randox kündigt weltweite Einführung eines automatisierten Biochemie-Assays für Herz-Fettsäure-bindendes Protein (H-FABP) an
Crumlin, England (ots/PRNewswire) – Hochsensible & -spezifische Biomarker myokardialer Ischämie können nun routinemässig für die Diagnose des akuten Koronarsyndroms (Acute Coronary Syndrome, ACS) verwendet werden. Das internationale klinische Diagnostikunternehmen Randox Laboratories hat heute einen automatisierten Laborassay für Herz-Fettsäure-bindendes Protein (H-FABP) lanciert, der die Diagnose und das Management von Patienten mit vermutetem akuten Koronarsyndrom (Acute Coronary [...]
New JUPITER Analysis Demonstrates CRESTORTM (rosuvastatin) Significantly Reduces Major Cardiovascular Events in High Risk Patients
London (ots/PRNewswire) – A post-hoc-analysis from JUPITER published in the European Heart Journal shows CRESTOR(TM) (rosuvastatin) 20 mg significantly reduced major cardiovascular (CV) events, defined as the combined end-point of CV death, stroke and myocardial infarction, compared to placebo, by 50% (p=0.028; CI 0.27-0.93) in high risk patients with a 10-year Framingham risk score >20% [...]
GIVE e.V. / Calcium und Vitamin D unentbehrlich für starke Knochen
Wölfersheim (ots) – Calciumpräparate können vielen Menschen gegen Knochenschäden und Osteoporose helfen, vor allem in Kombination mit Vitamin D. Darauf weist GIVE e.V. – die Gesellschaft zur Information über Vitalstoffe und Ernährung – hin. Die GIVE-Wissenschaftler warnen in diesem Zusammenhang vor einer unsachgemäßen Interpretation einer kürzlich erschienenen Untersuchung zur Auswirkung von Calcium-Supplementierung.* Die im British [...]
NEVO(TM) Sirolimus-Eluting Coronary Stent Continues to Demonstrate Excellent Safety and Efficacy Outcomes in New Twelve-Month Data
Paris, May 25, 2010 (ots/PRNewswire) – At 12 months the NEVO(TM) Sirolimus-eluting Coronary Stent has continued to demonstrate excellent safety and efficacy outcomes compared to Taxus(R) Liberte(R) according to new data presented today from the NEVO(TM) RES-I clinical trial. These results were presented as a late breaking trial at EuroPCR, the leading medical conference in [...]
Sanofi-aventis Initiates 10,000 Patient Study With Multaq(R) in Permanent Atrial Fibrillation
Paris, May 12, 2010 (ots/PRNewswire) – Sanofi-aventis announced today the initiation of a multinational, randomized, double-blind Phase IIIb trial, PALLAS, to assess the potential clinical benefit of Multaq(R) (dronedarone) in over 10,000 patients with permanent atrial fibrillation (AF) to reduce major adverse cardiovascular events. The announcement was made during Heart Rhythm 2010, the Heart Rhythm [...]
Abbott’s XIENCE V(R) Continues to Outperform TAXUS With Sustained Clinical Advantages and Impressive Long-Term Safety Results in SPIRIT III Trial
San Francisco (ots/PRNewswire) – – Market-Leading XIENCE V Demonstrates Single-Digit Rate of Major Adverse Cardiac Events (MACE) at Three Years and a 43 Percent Reduction vs. TAXUS – No Additional Stent Thrombosis between Two and Three Years, and Impressive Low Rate of Very Late Stent Thrombosis for XIENCE V Long-term data presented today from the [...]
CRESTOR(R) Reduced the Risk of Cardiovascular Events in Elderly Patients in New Analysis of JUPITER
Barcelona (ots/PRNewswire) – A new analysis from the JUPITER study showed that CRESTOR(R) (rosuvastatin) 20mg reduced the composite primary end point of major cardiovascular (CV) events (combined risk of myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from CV causes) by 39% (p
Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes
Paris (ots/PRNewswire) – – SEPIA-ACS Multiple-dose Phase II Results Showing 27- 42% Risk Reduction in ACS Complications Presented in Plenary Session of European Society of Cardiology Congress and Published in The Lancet Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the investigational anti-Xa intravenous anticoagulant otamixaban reduced by 27 to 42 percent the odds [...]
Neuer Biomarker "Copeptin" beschleunigt die Herzinfarktdiagnose
Hennigsdorf (ots) – Der neue Biomarker Copeptin kann das Patientenmanagement in der Notaufnahme entscheidend verbessern. Dies zeigt eine im “Journal of the American College of Cardiology” (JACC) veröffentlichte Studie, die sich mit der Bedeutung von Copeptin für den schnellen Ausschluss akuter Myokardinfarkte (AMI) befasst. Eine der größten Herausforderungen in der Notfallmedizin ist die frühe Diagnose [...]
World Heart Federation, Daiichi Sankyo and Lilly Partner to Improve Cardiovascular Health
Orlando, Florida (ots/PRNewswire) – The World Heart Federation, Daiichi Sankyo Company, Limited (TSE: 4568) and Eli Lilly and Company (NYSE: LLY) announced today that they have partnered to improve cardiovascular health internationally. The organizations made the announcement at the 58th Annual Scientific Session of the American College of Cardiology in Orlando, Florida. An estimated 17.5 [...]
Patients Receiving Haemodialysis for Treatment of End Stage Renal Disease did not Benefit From Statin Therapy in the AURORA Study
Orlando, Florida (ots/PRNewswire) – New data from the AURORA trial, a study in patients with end stage renal disease (ESRD) undergoing chronic haemodialysis, showed that there was no difference between rosuvastatin 10mg and placebo in reducing the combined endpoint of cardiovascular (CV) death, nonfatal stroke, and nonfatal myocardial infarction. During a median follow-up period of [...]
Cytori Stem & Regenerative Cell Heart Attack Trial Feasible & Safe
(pressebox) San Diego, 06.03.2009, Cytori Therapeutics, Inc. (NASDAQ: CYTX) completed enrollment in its APOLLO trial to evaluate the safety and feasibility of adipose tissue-derived stem and regenerative cells, processed with the Company’s Celution(R) System, in the treatment of severe heart attacks. The steering committee deemed, in concurrence with data safety and monitoring board (DSMB), that [...]
Diabetes Patients With High Triglycerides and Low HDL Cholesterol get the Most Benefit From Fenofibrate Treatment: New Data From the FIELD Study
Sydney (ots/PRNewswire) – Fenofibrate treatment reduces cardiovascular disease (CVD) risk (defined by total cardiovascular events: the composite of cardiovascular death, myocardial infarction, stroke, and coronary and carotid revascularization) in patients with type 2 diabetes and atherogenic dyslipidemia, that is, the combination of high triglyceride (2.3 mmol/L-200mg/dL or higher) and low high-density lipoprotein (HDL) cholesterol (
Richter-Helm and Athera Biotechnologies Partner in Development of Recombinant Protein to Treat Cardiovascular Disease
(pressebox) Hamburg, Germany and Stockholm, Sweden, 21.01.2009, Richter-Helm BioLogics GmbH & Co. KG and Athera Biotechnologies AB have signed an agreement for the development and manufacturing of Athera?s novel product for prevention of plaque rupture and athero-thrombosis through binding of the protein, Annexin A5, to endothelium. The recombinant protein Annexin A5 is intended for the [...]
